Trump Officials Offer Conflicting Views on Israel Policy During Transition

Market Reacts Coolly to Teva's New Strategic Plan

Teva aims to reduce its expenses by $1.5 billion to $2 billion a year thanks to $1 billion to $1.2 billion cuts in its costs of sales.

Since Jeremy Levin's appointment as CEO of Teva Pharmaceutical Industries at the beginning of last May, the company's stock has earned 1.6%, including...